{"id":"pegvisomant-sandostatin-lar","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Elevated liver transaminases"},{"rate":"null","effect":"Hyperglycemia"},{"rate":"null","effect":"Arthralgia"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Gallstones (with octreotide)"}]},"_chembl":{"chemblId":"CHEMBL1201515","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pegvisomant competitively antagonizes the growth hormone receptor, preventing GH-mediated effects on target tissues. Sandostatin LAR (octreotide) is a long-acting somatostatin analog that suppresses growth hormone and insulin-like growth factor-1 (IGF-1) secretion from the anterior pituitary. Together, they provide complementary mechanisms to reduce circulating GH and IGF-1 levels in acromegaly.","oneSentence":"Pegvisomant is a growth hormone receptor antagonist that blocks GH signaling, while Sandostatin LAR is a somatostatin analog that inhibits growth hormone secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:23:04.713Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acromegaly in patients inadequately controlled by surgery and/or radiotherapy, or as primary therapy when surgery/radiotherapy not an option"}]},"trialDetails":[{"nctId":"NCT01538966","phase":"NA","title":"Acromegaly Combination Treatment Study","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2012-03-29","conditions":"Acromegaly","enrollment":76},{"nctId":"NCT01278342","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-09","conditions":"Acromegaly","enrollment":70},{"nctId":"NCT02668172","phase":"PHASE4","title":"Pasireotide LAR and Pegvisomant Study in Acromegaly","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2015-08","conditions":"Acromegaly","enrollment":60},{"nctId":"NCT00068029","phase":"PHASE4","title":"Pegvisomant And Sandostatin LAR Combination Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-10","conditions":"Acromegaly","enrollment":75},{"nctId":"NCT00068042","phase":"PHASE4","title":"A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-04","conditions":"Acromegaly","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Pegvisomant/ Sandostatin LAR","genericName":"Pegvisomant/ Sandostatin LAR","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegvisomant is a growth hormone receptor antagonist that blocks GH signaling, while Sandostatin LAR is a somatostatin analog that inhibits growth hormone secretion. Used for Acromegaly in patients inadequately controlled by surgery and/or radiotherapy, or as primary therapy when surgery/radiotherapy not an option.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}